First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi

摘要

(*) Patients in response were allowed to undergo ASCT after 2 cycles in case of severe toxicity (see text for details). IR, infusion reaction; ASCT, autologous stem cell transplantation; PBSC, peripheral blood stem cells; and G-CSF, granulocyte colony-stimulating factor.